Cargando…

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

BACKGROUND: Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments. METHODS: Patients with ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bratt, O, Häggman, M, Ahlgren, G, Nordle, Ö, Björk, A, Damber, J-E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768463/ https://www.ncbi.nlm.nih.gov/pubmed/19755981 http://dx.doi.org/10.1038/sj.bjc.6605322

Ejemplares similares

Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer
por: Gupta, Neha, et al.
Publicado: (2014)

Mechanisms of action of tasquinimod on the tumour microenvironment
por: Raymond, E., et al.
Publicado: (2013)

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer
por: Corcoran, N M, et al.
Publicado: (2010)

Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials
por: Gong, Ping, et al.
Publicado: (2018)

A review of tasquinimod in the treatment of advanced prostate cancer
por: Williamson, Stuart Charles, et al.
Publicado: (2013)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2017)

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
por: Nabhan, C, et al.
Publicado: (2012)

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015)

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors
por: Olsson, Anders, et al.
Publicado: (2010)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
por: Shamash, J, et al.
Publicado: (2011)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
por: Kruczek, K, et al.
Publicado: (2013)

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
por: Beer, T M, et al.
Publicado: (2012)

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
por: Bianchini, D, et al.
Publicado: (2013)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Osteoclasts directly influence castration-resistant prostate cancer cells
por: Huang, Junchi, et al.
Publicado: (2022)

Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer
por: de Liaño, A G, et al.
Publicado: (2014)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma
por: Shaw, D M, et al.
Publicado: (2007)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases
por: Sartor, O., et al.
Publicado: (2017)

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.
por: Westin, P., et al.
Publicado: (1995)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2016)

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment
por: Olsson, Anders, et al.
Publicado: (2015)

Low-Dose Chemotherapy with Insulin (Insulin Potentiation Therapy) in Combination with Hormone Therapy for Treatment of Castration-Resistant Prostate Cancer
por: Damyanov, Christo, et al.
Publicado: (2012)

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
por: Madan, Ravi A., et al.
Publicado: (2023)

An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
por: Belderbos, Bodine P. S. I., et al.
Publicado: (2018)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Castration for Prostatic Hypertrophy
Publicado: (1899)

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
por: Drake, M J, et al.
Publicado: (2003)

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer
por: Scholz, Mark, et al.
Publicado: (2017)

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
por: Dalgleish, Angus G, et al.
Publicado: (2016)

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
por: Trainer, Peter J, et al.
Publicado: (2018)

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
por: du Bois, A, et al.
Publicado: (2012)

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014)

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
por: Crespo, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_stptl1p43lpqehb62gq8tb82ar